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Abstract
Dendritic cells (DC) used in therapeutic cancer immunotherapy have to be able to stimulate T cells resulting in an immune
response that can efficiently target the cancer cells. One of the critical hurdles has been the lack of IL-12p70 production
when maturating the DC, which is rectified by using the bacterial preparation OK432 (trade name Picibanil) to mature the
cells. In order to identify the mechanism behind OK432 stimulation of DC, we investigated the contribution of different TLR
to examine their involvement in IL-12p70 production. By combining different inhibitors of TLR signaling, we demonstrate
here that TLR3 is responsible for the IL-12p70 production of DC induced by OK432. Moreover, our data suggest that the
ligand triggering IL-12p70 secretion upon TLR3 stimulation is sensitive to proteinase and partly also RNAse treatment. The
fact that a bacterial compound like OK432 can activate the TLR3 pathway in human DC is a novel finding. OK432
demonstrates a critical ability to induce IL-12p70 production, which is of great relevance in DC based cancer
immunotherapy.
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Introduction
Dendritic cells (DC) are the sentinels of the immune system and
at the crossroad of the innate and adaptive immunity. Due to their
outstanding capacity to stimulate T cells, there is a considerable
interest of employing these qualities in various forms of
immunotherapy [1,2]. In DC-based cancer immunotherapy one
of the critical hurdles has been the lack of IL-12p70 production
when stimulating the DC with the Jonuleit cytokine cocktail (IL-
1b, IL-6, TNF-a and PGE2 [3], which is the most commonly used
maturation stimulus in clinical trials. To find a better way to
stimulate DC used in cancer immunotherapy, a range of stimuli
has been tested [4]. The maturation stimulus of choice must
induce a functional maturity of the DC resulting in a superior T
cell stimulation that can efficiently target the cancer cells. To fulfill
these criteria we have investigated the low-virulence strain of
penicillin-killed Streptococcus pyogenes (OK432) [5]. OK432 is
available as a licensed drug (trade name, Picibanil) and has been
used efficiently to treat a variety of tumors [6,7] both alone or in
combination with chemotherapy [8]. The effect of OK432 in
cancer patients has not been thoroughly investigated, but we have
recently shown that OK432 induces production of substantial
amounts of IL-12p70 and other inflammatory cytokines by human
monocyte-derived DC in vitro [9]. Furthermore, OK432 induces
up-regulation of surface expression of MHC class II molecules as
well as a number of co-stimulatory molecules on DC. Moreover,
OK432 stimulated DC have an increased T cell stimulatory
capacity [9].
The mechanism behind OK432 stimulation of DC at the
cellular level is not well understood, and there is conflicting
evidence in the literature. Both p38 MAPK, TLR4 and b2 integrin
have been proposed as the key component in OK432 mediated
DC maturation and cytokine release [10–14], possibly in an
orchestrated manner as b2 integrin has been shown to co-localize
with TLR4 in lipid rafts in mouse b hepatocytes [15]. However, an
antitumor effect of OK432 was also seen in TLR42/2 mice [14]
and Nakahara and co-workers found OK432 to act independent
of TLR2 and TLR4, but dependent on b2 integrin [11]. The
active ingredient of OK432 has been proposed to be a lipoteichoic
acid-related molecule [16] which would normally point to an
involvement of TLR2 [17].
To ease the transition of OK432 into a clinical protocol using
OK432 stimulated DC in therapeutic cancer vaccination, the aim
of this study was to explore the mechanisms behind the ability of
OK432 to stimulate DC and to elicit high IL-12p70 secretion. To
this end we investigated the contribution of different TLR in
OK432 mediated IL-12p70 production. By combining inhibitors
of TLR signaling, we were able to demonstrate that TLR3 is
responsible for the OK432 induced IL-12p70 production by DC.
We have also obtained evidence that the ligand triggering IL-
PLoS ONE | www.plosone.org 1 February 2012 | Volume 7 | Issue 2 | e3121712p70 secretion upon TLR3 stimulation is sensitive to proteinase
and partly also RNAse treatment.
Results
Chloroquine, but not TLR4 and MyD88 inhibition,
abrogates OK432 mediated IL-12p70 production
In order to decipher the mechanism behind OK432 stimulation
of DC, we utilized various compounds inhibiting TLR signaling,
as TLR involvement was likely with a bacterial compound like
OK432. As the induction of IL-12p70 was of high interest, we
chose IL-12p70 secretion as the primary readout, and expression
of cell surface markers as secondary readout only.
To verify or exclude involvement of TLR4, we utilized a
blocking antibody against this receptor. However, blocking of
TLR4 failed to reduce the level of IL-12p70 production after
OK432 stimulation (Figure 1A). In order to ensure that the
antibody was functional and the concentration used was sufficient,
we included LPS as a positive control. Incubation of the cells with
the blocking antibody against TLR4 reduced the level of LPS
induced IL-12p70 secretion by 50% (Figure 1B).
Most TLR signal via the MyD88 adaptor protein, with the
exception of TLR3 and one of the pathways of TLR4 [18]. In
order to block all signaling via MyD88, an inhibitory peptide was
utilized. The MyD88 inhibitory peptide was toxic at high
concentrations and therefore titrated to not influence cellular
viability, with an optimal concentration found to be 100 mM. At
this concentration the inhibitory MyD88 peptide did not reduce
the level of IL-12p70 detected after OK432 stimulation
(Figure 1A), demonstrating that OK432 induced IL-12p70
production is not mediated via the MyD88 pathway. To ensure
that the concentration used was sufficient to block signaling via
MyD88, we used MyD88 dependent TLR7/8 ligand CL097 as
positive control. The inhibitory peptide completely abolished IL-
12p70 production induced by CL097 (Figure 1C).
Chloroquine is a compound that recently has been shown to
stop signaling of TLR3 and 9 localized in endosomes by directly
binding of nucleic acids masking their TLR-binding epitope [19].
Due to its toxicity the chloroquine was titrated to achieve efficient
signaling blockade of the endosomes, while not influencing the
cellular viability. The optimal concentration was found to be
40 mM both for immature and stimulated DC. At this concentra-
tion, chloroquine completely blocked all IL-12p70 production
after OK432 stimulation, demonstrating that the production of IL-
12p70 is dependent on a functional endosome (Figure 1A).
Inhibition with chloroquine also led to a reduction of median
fluorescence intensity (MFI) of surface CD40, CD1a, and HLA-
DR by around 50% and a reduction of CD86 MFI by 30%
(Figure 1D). Little effects were seen on CD83, CD80, CCR7 and
CD38 expression (data not shown). This, together with the IL-
12p70 reduction, demonstrates a phenotypic effect and a reduced
maturation of OK432 stimulated DC pre-treated with chloro-
quine.
TLR3 siRNA inhibit the IL-12p70 production after OK432
stimulation in a dose-dependent manner
The previous experiments indicated involvement of either
TLR3 or MyD88 independent TLR4. To resolve this, siRNA
against TLR3 was utilized to block signaling via TLR3. Two
different TLR3 siRNA were electroporated 24 hours prior to
OK432 stimulation. The level of protein expression of TLR3 was
reduced by around 40% after 48 h (harvest of cells and medium)
as measured by flow cytometry (Figure 2A). The TLR3 siRNA
were able to reduce the level of IL-12p70 production by 80–100%
after OK432 stimulation (Figure 2B). This effect was specific as a
control siRNA did not reduce IL-12p70 levels, and the effect was
dose dependent (Figure 2C). The knock down effect was also
obvious on a number of surface markers associated with DC
maturation with reduction of expression from 25 to over 80%
(Figure 2D). As a control of the successful TLR3 knock down,
50 mg/ml polyI:C was used as a positive control to stimulate
TLR3 siRNA treated DC. The level of IL-12p70 was reduced by
close to 90% (Figure 2E). Moreover, the effect was not due to
differences in viability, as the siRNA treated cells produced the
same amounts of IL-8 as mock treated DC (Figure S1).
The TRIF pathway is critical to elicit IL-12p70 production
To further strengthen the involvement of TLR3 signaling in
OK432 stimulation of DC, a TRIF inhibitory peptide was
employed to demonstrate dependence on this pathway for IL-
12p70 secretion. The TRIF inhibitory peptide and the control
peptide were carefully titrated as they both were toxic to the DC at
high concentrations. At an optimal concentration, the TRIF
inhibitory peptide showed an inhibition of the IL-12p70
production upon OK432 stimulation in a dose dependent manner,
further demonstrating that OK432 mediated IL-12p70 production
is dependent on a functional TRIF pathway (Figure 3). Only little
effect was seen on the phenotype of the cells (data not shown).
OK432 mediated IL-12p70 production is dependent on
intact RNA and protein present
To elucidate the nature of the TLR3 ligand by which OK432
stimulates DC to produce IL-12p70, the OK432 compound was
treated with combinations of protease K, DNase I and RNase A
prior to addition to DC. With OK432 alone set to 100%, DNase
treatment of OK432 had no effect on IL-12p70 secretion (data not
shown). Protease K reduced IL-12p70 production by 50–100% in
a dose dependent manner, whereas RNase A reduced IL-12p70
production by 20–50% depending on the concentration (Figure 4).
In combination, protease and RNase A reduced IL-12p70
secretion by almost 90%. The effect of RNase A treatment of
OK432 on IL-12p70 production could be rescued by adding an
RNase inhibitor into the pre-treatment mix. Therefore, our data
suggest that the bacterial compound OK432 exerts its effect on
TLR3 mediated IL-12p70 production with a ligand that requires
protein and is augmented by the presence of intact RNA.
Discussion
OK432 has been used clinically for several decades against
malignant and benign neoplasms with excellent safety profile [5–
8,10,20]. In the last decade, it has also attracted some interest as
maturation stimulus in DC-based therapeutic cancer vaccination
protocols [9,11,14,21–24]. However, until now the mechanism
behind OK432 stimulation of DC has been elusive.
We therefore set out to work out the pathways activated by
OK432. Our inhibition experiments demonstrated that OK432
and IL-12p70 production is dependent on a functioning
endosome. The MyD88 inhibition showed that IL-12p70
production is not dependent on MyD88 signaling and therefore
point to TRIF dependent TLR4 signaling or TLR3. However, if
OK432 had been dependent on TLR4, the IL-12p70 should not
be completely blocked by chloroquine as demonstrated. CCL5/
Rantes has been linked to TLR3 activation in epithelial cells [25]
and consistently, we have previously found a marked up-regulation
of CCL5 upon OK432 stimulation of DC [9]. The fact that a
significant antitumor activity after OK432 treatment was also seen
in TLR42/2 mice [14] points to other TLR having a significant
OK432 Is a TLR3 Agonist
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level of IL-12p70 induced by LPS via the TLR4 pathway was only
about 3% of that of OK432 alone. We observed an almost total
block of IL-12p70 secretion after TLR3 knock down. This effect
was specific as a control siRNA did not reduce IL-12p70, and the
effect was dose-dependent. TRIF inhibition was also shown to be
dose-dependent, but due to the cellular toxicity of the inhibitory
peptide, only a 50% reduction of IL-12p70 production was
achieved. Comparison of OK432 and TLR3 ligand polyI:C
revealed that polyI:C was inferior to OK432 in eliciting IL-12p70
Figure 1. Chloroquine treatment abolishes IL-12p70 production by DC stimulated with OK432. A) Combinations of blocking antibody to
TLR4, MyD88 inhibitory peptide and chloroquine were used to decipher contributions of different TLR in IL-12p70 production by DC after OK432
stimulation. The DC were pre-treated with the indicated compounds for 30 minutes at 37uC before maturation was induced by OK432. Immature DC
were given only IL-4 and GM-CSF and Cyto were stimulated with the Jonuleit cytokine cocktail (IL-1b, IL-6, TNF-a and PGE2). Only treatment with
chloroquine reduced the level of IL-12p70 produced after OK432 stimulation. Mean+SEM is shown for 4 donors. B) To verify the effect of TLR4
blockade, a blocking antibody against TLR4 was used at 9 mg/ml. This reduced the level of LPS (20 ng/ml) induced IL-12p70 production by 50%. Mean
of n=2. C) MyD88 inhibition effectively decreases CL097 mediated IL-12p70 production via TLR7/8 signaling. D) Chloroquine has profound effects on
the maturation status of OK432 stimulated DC. Percent MFI of CD1a, HLA-DR, CD86 and CD40 after pre-treating the DC with chloroquine before
OK432 stimulation compared to OK432 alone (set to 100 percent) is shown. One representative experiment shown of three performed.
doi:10.1371/journal.pone.0031217.g001
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with polyI:C in a maturation cocktail would not be sufficient to
induce equivalent amounts of IL-12p70.
OK432 mediated maturation of DC has been attributed to
several receptors, like TLR4, p38 MAPK and the b2 integrin [10–
14]. The active component of OK432 has been suggested to be a
lipoteichoic acid-related molecule [16], normally a ligand for
TLR2 [17]. Nakahara and co-workers found OK432 stimulation
to be independent of TLR2 and TLR4 [11], which is in line with
our finding that TLR3 is a critical part of OK432 induced IL-
12p70 production. As we are interested in the use of OK432 as
part of a clinical protocol, we chose to focus on the IL-12p70
production as it is critical to ensure a good cytotoxic T cell
response [26]. This does not exclude other pattern recognition
receptors (PRR) to recognize components of OK432 that
contribute to DC maturation. As OK432 is a compound made
from a whole bacterium it is to be expected that several PRR
participate in subsequent DC signaling. This is substantiated by
the fact that TLR3 siRNA knock down, chloroquine treatment
and TRIF inhibition sufficient to reduce IL-12p70 production by
50–100% only to some extent showed an effect on the DC
phenotype.
Other PRR that recognize nucleic acids like RIG-I-like RNA
helicases and melanoma differentiation-associated gene 5, reside in
the cytosol [27,28] and therefore no effect should be seen after
chloroquine, TLR3 siRNA and inhibitory TRIF treatment. That
does not exclude other PRR like nucleotide-binding oligomeriza-
tion domain containing 2 (NOD2) augmenting IL-12p70 produc-
tion, like Tada et al. reported for NOD2 ligands and TLR
including TLR3 [29]. It is also possible and even likely that other
PRR contribute to the induction of the inflammatory environment
seen after OK432 stimulation of DC. Although TLR3 induced
IRF3 has been verified as an important mechanism to induce type
I interferons such as IFN-b [30,31], also NOD2 has been found to
induce IRF3 [32]. Moreover, TLR3 induced NF-kB and AP-1 is
responsible for induction of pro-inflammatory cytokines [33].
Figure 2. TLR3 knockdown has a considerable effect on OK432 induced IL-12p70 production by DC. A) DC were electroporated with
either control siRNA that has no specific target in human cells or with two siRNA specific against TLR3. The level of siRNA mediated TLR3 knockdown
was found to be around 40 percent after 24 hours of OK432 stimulation (48 h after electroporation). Open histogram: unstained control; shaded
histogram: mock treated; black histogram: TLR3 siRNA treated; one representative experiment shown of five. B) After resting for 24 hours, the DC
were incubated with OK432 for 24 hours and the supernatant was collected and analyzed for IL-12p70 production by ELISA. OK432 is critically
dependent on TLR3 signaling to induce IL-12p70 production. Immature cells (Imm) received only IL-4 and GM-CSF, the Cyto group were matured
with IL-1b, IL-6, TNF-a and PGE2. Mean+SEM are shown for four donors. C) To further verify the specificity of the TLR3 siRNA knock down, DC were
electroporated with escalating concentrations of TLR3 siRNA and rested for 24 hours. Subsequently, after 24 hour stimulation with OK432, IL-12p70
production was analyzed. One representative donor is shown out of three. D) TLR3 siRNA knockdown has a marked effect on the phenotype of
OK432 matured DC. Percent MFI of CD1a, HLA-DR, CD86 and CD40 after TLR3 siRNA knock down and OK432 stimulation compared to OK432 plus
control siRNA (set to 100%). Mean of two donors shown. E) TLR3 siRNA inhibit IL-12p70 production upon polyI:C stimulation of DC. IL-12p70
production of polyI:C treated DC were set to 100%. One representative donor is shown.
doi:10.1371/journal.pone.0031217.g002
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over 40–50 nucleotides long, due to the distance between dimers
of TLR3 [34,35]. OK432 could harbor RNA in a manner
untypical of a bacterium, either intrinsically, or as a consequence
of the OK432 manufacturing process. Our data suggest that the
ligand from OK432 mediating IL-12p70 production via TLR3 is
sensitive to RNase A, which has ssRNA specificity under
physiological conditions [36] and protease K. As both protein
and RNA need to be present, one may speculate that a bacterial
protein is needed to promote the correct secondary structure of
bacterial RNA in order to have an efficient TLR3 ligation. This is
supported by the fact that also mRNA has been reported to be
able to activate TLR3 mediated signaling [37] and Marshall-
Clarke co-workers reported that in murine immune cells, including
DC, the single stranded synthetic polyinosinic acid could mediate
signaling via TLR3 [38].This is also in concordance with our
observation that reconstituted OK432 loses its IL-12p70 eliciting
capacity rapidly over days stored at 4uC. Furthermore, Derbigny
and co-workers have recently reported TRIF dependent IFN-b
production after Chlamydia infection of murine macrophages and
attributed this to TLR3 mediated signaling [39]. It has also been
suggested that dsRNA from helminths can activate TLR3 in
murine DC [40].
In conclusion, our results together with the above mentioned
study by Derbigny et al. suggest that TLR3 signaling is a common
feature for both murine and human immune cells in response to at
least some bacteria. This can have direct consequences for the
ongoing quest to find suitable maturation stimuli for DC-based
therapeutic cancer vaccines. OK432 is certainly able to induce a
range of inflammatory mediators, among them the critical IL-
12p70, a key cytokine in eliciting cytotoxic T cell mediated
immunity.
Materials and Methods
DC generation
DC were generated from monocytes isolated from buffy coat
preparations from healthy blood donors (Blood Bank, Haukeland
University Hospital, Bergen, Norway) as described [9]. Briefly,
peripheral blood mononuclear cells were separated by a density
gradient centrifugation and the monocytes were then negatively
isolated using the Dynabeads Untouched Human Monocytes
(Invitrogen, Carlsbad, CA) following the manufacturer’s instruc-
tions. The monocytes were cultured with IL-4 (20 ng/ml;
Immunotools, Friesoythe; Germany) and GM-CSF (100 ng/ml;
Immunotools, Friesoythe; Germany) in RP10 medium [RPMI
1640 (Cambrex Bioscience, Verviers, Belgium) with 10% FCS
(PAA, Pasching, Austria); 100 units/ml penicillin and 100 mg/ml
streptomycin (Sigma-Aldrich, St. Louis, MO)] for 5–6 days to
generate immature DC. Cytokines were replenished every 2–3
days. The maturation of the cells was performed for 24 hours with
the Jonuleit cytokine cocktail [IL-1b, 10 ng/ml; IL-6, 1000 U/ml;
TNF-a 10 ng/ml (all from Immunotools, Friesoythe; Germany)
and PGE2,1 mg/ml (Sigma-Aldrich, St. Louis, MO)] or with
OK432 (Picibanil, Chugai Pharmaceutical Co. Ltd, Tokyo,
Japan). The dosage of OK432 was 0.1 Klinische Einheit (KE),
where 1 KE equals approximately 0.1 mg.
Inhibition of TLR signaling
To block TLR4 signaling, a polyclonal blocking antibody (Anti-
hTLR4-lgA, Invivogen, San Diego, CA) was used at a titrated
concentration, 9 mg/ml. Chloroquine (Sigma-Aldrich, St. Louis,
MO) was utilized to inhibit TLR signaling from the endosomal
compartment at a titrated, non-toxic concentration (40 mM). To
analyze any involvement of signaling via MyD88, a blocking
peptide hindering MyD88 dimerization was utilized (100 mM,
IMG-2005, Imgenex, San Diego, CA). A TRIF inhibitory peptide
(Pepinh-TRIF, Invivogen) was used to block signaling via the
TRIF pathway at a titrated concentration of 50 mM. Appropriate
control peptides were included in all experiments. Two TLR3
Figure 3. OK432 induced IL-12p70 production is TRIF depen-
dent. Pre-treating the DC for 30 minutes at 37uC with an inhibitory
peptide of TRIF signaling reduced the level of OK432 induced IL-12p70
production in a dose dependent manner compared to a control peptide
and OK432. Concentrations higher than 20 mM had a toxic effect on the
DC. Data from one representative donor is shown.
doi:10.1371/journal.pone.0031217.g003
Figure 4. OK432 mediates its effect via TLR3 by a ligand that
needs RNA and protein present. OK432 was pre-treated with RNase
A and protease K for 30 minutes at 37uC before being diluted 25-fold
and added to the DC. The pre-treatment was performed with 100, 10
and 2 mg/ml protease K, and RNase A was tested at 100, 10 and 1 mg/
ml. After 24 hours the supernatants were analyzed for presence of IL-
12p70. The amount produced is displayed as a percentage compared to
that of OK432 alone set to 100%. Protease K treatment diminished IL-
12p70 production in a dose-dependent manner. RNase reduced the IL-
12p70 production by more than 50%, while the combination of
protease K and RNase treatment reduced the IL-12p70 production by
around 90%. IL-12p70 production was rescued by adding a RNase
inhibitor together with the pre-treatment. For each treatment, the
mean and SEM is shown (N=2–4 experiments).
doi:10.1371/journal.pone.0031217.g004
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delivered by square wave electroporation (500 V, 1 ms; ECM 830,
BTX, Holliston, MA). TLR3 down-regulation was analyzed after
24 and 48 hours by intracellular staining of TLR3. OK432 and
cytokine cocktail matured DC were included in all experiments as
controls and the level of IL-12p70 production was normalized to
production of OK432 treated DC to compensate for donor
variations. In order to disclose the nature of the ligand responsible
for inducing IL-12p70 production, OK432 was pre-incubated
with DNase I (Sigma-Aldrich, St. Louis, MO), RNase A,
RiboLock nuclease inhibitor (2 U/ml) and protease K (all
Fermentas, St. Leon-Rot, Germany). The concentrations used
were 100 mg/ml, 10 mg/ml and 2 mg/ml of protease in 40 ml
volume; 100 mg/ml, 10 mg/ml and 1 mg/ml RNase A in 40 ml and
2 U DNase in 10 ml for 30 minutes at 37uC. This was followed by
diluting OK432 to a final concentration of 0.1 KE in 1 ml total
volume. To avoid unwanted degradation of OK432 no inactivat-
ing of enzymes was performed.
Flowcytometry
Immunostaining was performed as described previously [9].
Briefly, the cells were incubated with titrated amount of antibodies
for 10 minutes at room temperature before the cells were washed
and immediately analyzed on a FACSCanto I cytometer (BD
Biosciences, Heidelberg, Germany). All subsequent analyses were
done with FlowJo software (Tree Star, Ashland, OR). The
antibodies used were CD1-PE (NA1/34-HLK), CD14-FITC
(UCHM1), CD38-Alexa Fluor 647(AT13/5), CD86-FITC
(BU63), CD83-PE (HB15e), CD80-APC (MEM-233), CD40-
FITC (LOB7/6), HLA-DR-APC (HL-39; all from AbD Serotec,
Du ¨sseldorf, Germany), and CCR7-PE (150503; R&D Systems,
Minneapolis, MN).
Cytokine determination
A sandwich ELISA was used to determine the amount of
secreted IL-12p70 (BioLegend, San Diego, CA) according to the
manufacturer’s instructions.
Supporting Information
Figure S1 TLR3 siRNA treated DC produce similar
amounts of IL-8 as mock treated DC. DC were either mock
treated or electroporated with either control siRNA that has no
specific target in human cells or with two siRNA specific against
TLR3. IL-8 production was measured by commercially available
sandwich ELISA (R&D systems) to evaluate the viability of the
cells. The amount IL-8 produced is displayed as a percentage
compared to that of mock treated cells set to 100%. Mean and
SEM is shown (N=3 experiments).
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